The combined entity will operate under the Fortitude banner, trading under the ticker symbol TUDE once regulatory hurdles clear. While the two firms occupy vastly different sectors, the merger functions as a strategic pivot for HeartSciences, which has struggled with profitability, reporting a $8.77 million net loss for fiscal 2025. CEO Andrew Simpson stated the move aims to break the company's cycle of perpetual capital raising, positioning the business for a more stable financial trajectory.
Fortitude brings significant scale to the arrangement, reporting an annualized production of 157,000 Zcash as of May 31. This integration arrives as privacy-focused digital assets regain market traction amid tightening European regulatory frameworks. While HeartSciences continues its work on the MyoVista Insights ECG platform, the company’s existing shareholders will retain a minority stake in the new, crypto-centric enterprise, effectively handing control of the public listing to Fortitude’s management team.

Comments (0)
No comments yet. Be the first!